Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells-Reference-Cited by-同舟云学术

Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells

Published:1992-04 Issue:4 Volume:118 Page:269-275
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

van Valen F.,Winkelmann W.,Jürgens H.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF01208615.pdf

Reference35 articles.

1. Adashi EY, Resnick CE, Rosenfeld RG (1989) Insulin-like growth factor-I (IGF-I) and IGF-II hormonal action in cultured rat granulosa cells: mediation via type I but not type II IGF receptors Endocrinology 126:216?222

2. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M (1991) MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Cancer 67:1886?1893

3. Casella SJ, Han VK, D'Ercole AJ, Svoboda ME, Van Wyk JJ (1986) Insulin-like growth factor II binding to the type I somatomedin receptor. Evidence for two high affinity binding sites. J Biol Chem 261:9268?9273

4. Cavazzana AO, Miser JS, Jefferson J, Triche TJ (1987) Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol 127:507?518

5. Czech MP (1989) Signal transmission by the insulin-like growth factors. Cell 59:235?238

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma;Cancer Medicine;2023-06-12

2. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group;Journal of Clinical Oncology;2023-04-10

3. Role of immunotherapy in Ewing sarcoma;Journal for ImmunoTherapy of Cancer;2020-12

4. Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma;Frontiers in Oncology;2019-06-19

5. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2;Oncotarget;2017-09-28